Most Alzheimer’s Patients Wouldn’t Have Qualified for Controversial Drug’s Trial: Study
TUESDAY, Sept. 14, 2021 (HealthDay News) — U.S. approval of the Alzheimer’s drug Aduhelm is already mired in controversy. Now a new study finds that most Alzheimer’s patients could not have taken part in clinical trials that led to the green light. In June, the U.S. Food and Drug AdministrationContinue Reading